RxDoctor Payments Data

Anthony Sayegh, DO

Family Medicine · Sterling Heights, MINPI 1114961885

Payments from drug & device makers

$4,663in general payments, 2019–2025

Across 263 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$959
  • Boehringer Ingelheim$671
  • Lilly USA, LLC$371
  • GSK$278
  • Edwards Lifesciences$138
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$4,63099%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,663 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$85,784
Medicare patients
126
Services billed
1,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$58,662
FarxigaDapagliflozin Propanediol24$29,817
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$29,638
TrulicityDulaglutide22$25,088
JardianceEmpagliflozin15$14,576
LinzessLinaclotide13$7,481
ShingrixVaricella-Zoster Ge/As01b/Pf21$4,637
Atorvastatin Calcium332$4,249
Ezetimibe110$2,754
SynthroidLevothyroxine Sodium23$2,254
Rosuvastatin Calcium117$2,201
Omega-3 Acid Ethyl Esters28$2,087
Pravastatin Sodium88$1,756
Metoprolol Succinate64$1,670
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,052$58,66251 claims
GSKTrelegy Ellipta, Shingrix$278$34,27542 claims
AstraZenecaFarxiga$107$29,81724 claims
Lilly USA, LLCTrulicity$371$25,08822 claims
Boehringer IngelheimJardiance$671$14,57615 claims
AbbVieLinzess, Synthroid$53$9,73536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Sterling Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →